Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland

Active, not recruiting

Conditions: Inflammatory Bowel Disease (IBD)
Crohn's Disease
Ulcerative Colitis

First Posted Date: 2022-05-20

Last Posted Date: 2024-10-09

Lead Sponsor: Takeda

Target Recruit Count: 165

Registration Number: NCT05384080

Locations: 🇵🇱
Uniwersytecki Szpital Kliniczny, Wroclaw, Dolnoslskie, Poland
🇵🇱
Szpital Uniwersytecki w Krakowie, Krakow, Malopolskie, Poland
🇵🇱
Samodzielny Publiczny Szpital Kliniczny Nr 4 W Lublinie, Lublin, Lubelskie, Poland

and more 8 locations

Maribavir Food-Effect Study in Healthy Adults Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Maribavir

First Posted Date: 2022-05-19

Last Posted Date: 2024-02-16

Lead Sponsor: Takeda

Target Recruit Count: 31

Registration Number: NCT05382104

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada

Recruiting

Conditions: Short Bowel Syndrome (SBS)

Interventions: Other: Non-interventional Study

First Posted Date: 2022-05-12

Last Posted Date: 2024-12-17

Lead Sponsor: Takeda

Target Recruit Count: 100

Registration Number: NCT05371028

Locations: 🇨🇦
Innomar Strategies, Oakville, Ontario, Canada

A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Completed

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

First Posted Date: 2022-05-05

Last Posted Date: 2023-05-01

Lead Sponsor: Takeda

Target Recruit Count: 6086

Registration Number: NCT05363358

Locations: 🇺🇸
RTI Health Solutions, Durham, North Carolina, United States

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Phase 2

Completed

Conditions: Celiac Disease

Interventions: Drug: TAK-062
Dietary Supplement: Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar
Drug: TAK-062 Placebo
Dietary Supplement: Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar

First Posted Date: 2022-04-29

Last Posted Date: 2024-11-28

Lead Sponsor: Takeda

Target Recruit Count: 153

Registration Number: NCT05353985

Locations: 🇺🇸
Medical Associates Research Group, Inc., San Diego, California, United States
🇵🇱
Komisja Bioetyczna przy Okregowej Izbie Lekarskiej w Warszawie, Warszawa, Poland
🇮🇹
Ospedale Umberto I di Torino S.C. Gastroenterologia, Torino, Italy

and more 98 locations

A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Phase 4

Recruiting

Conditions: Central Precocious Puberty

Interventions: Drug: Leuprorelin Acetate Depot 3M

First Posted Date: 2022-04-22

Last Posted Date: 2024-02-12

Lead Sponsor: Takeda

Target Recruit Count: 80

Registration Number: NCT05341115

Locations: 🇨🇳
Shanghai Children's Hospital, Shanghai, Shanghai, China
🇨🇳
Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
🇨🇳
The Hospital attached by the Torigji Medical College, Huazhong Science and Technology University., Wuhan, Hubei, China

and more 2 locations

A Study of Medical Records From Children With Central Precocious Puberty (CPP) in China

Not yet recruiting

Conditions: Central Precocious Puberty

First Posted Date: 2022-04-22

Last Posted Date: 2024-02-23

Lead Sponsor: Takeda

Target Recruit Count: 400

Registration Number: NCT05341128

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

Phase 3

Active, not recruiting

Conditions: Cytomegalovirus (CMV)

Interventions: Drug: Maribavir

First Posted Date: 2022-04-08

Last Posted Date: 2024-12-10

Lead Sponsor: Takeda

Target Recruit Count: 80

Registration Number: NCT05319353

Locations: 🇧🇷
Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷
Hospital de Clinicas de Porto Alegre (HCPA) - PPDS, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Porto Alegre, Rio Grande Do Sul, Brazil

and more 44 locations

A Survey of Midazolam in People With Status Epilepticus

Recruiting

Conditions: Epilepsy

Interventions: Drug: Midazolam

First Posted Date: 2022-04-06

Last Posted Date: 2024-04-12

Lead Sponsor: Takeda

Target Recruit Count: 50

Registration Number: NCT05313308

Locations: 🇯🇵
Takeda selected site, Tokyo, Japan

Virtual Celiac Symptoms Study in Adults and Teenagers

Completed

Conditions: Celiac Disease

Interventions: Other: No Intervention

First Posted Date: 2022-04-04

Last Posted Date: 2023-03-10

Lead Sponsor: Takeda

Target Recruit Count: 480

Registration Number: NCT05309330

Locations: 🇺🇸
Takeda, Lexington, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy